HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Clinical Trial: Iberdomide Alone or With Dexamethasone in Smoldering Myeloma
Posted: Nov 03, 2022
Clinical Trial: Iberdomide Alone or With Dexamethasone in Smoldering Myeloma image

Several clinical trials are taking place right now at trying to prevent smoldering myeloma from progressing to active myeloma. One clinical trial open at Emory University is using a drug called iberdomide which has immunomodulating and cancer killing activities. This means that it helps to induce myeloma cell death and at the same time it helps the immune system to be stronger (by activating T-lymphocytes). 

The iberdomide clinical trial is a Phase II study including 68 participants that aims to evaluate the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread.

The study is broken into two groups where one group of patients will receive iberdomide and dexamethasone (Arm A); while the other group will receive iberdomide alone (Arm B). Patients can join the study if they have/are: 

  • Intermediate or high risk smoldering multiple myeloma (SMM)
  • Diagnosed with SMM less than 5 years from initiation of study drug
  • Both men and women of all races and ethnic groups
  • Patients with no kidney/heart issues

The study will review the overall response rate (ORR) comparing the two arms. It will also review: 

  • The 1- and 2- year progression free survival rates
  • The time to progression, and overall survival
  • To study the risk of adverse hematologic and non-hematologic events
  • To evaluate stem cell mobilization failure and early stem cell mobilization feasibility

Patients can join if they have intermediate or high-risk smoldering multiple myeloma that includes at least one of the following risk factors:

  • Bone marrow clonal plasma cells >= 20% confirmed on either screening bone marrow biopsy or by outside pathology ≤5 years from initiation of study drug.
  • Abnormal serum free light chain ratio > 20 by serum free light chain (FLC) assay
  • Serum monoclonal protein >= 2 g/dL

How We Can Help

If you need assistance finding or joining clinical trials, please contact our Patient Navigator support team at 1-800-709-1113 or at support@healthtree.org.

Did you know you can find more clinical trials in HealthTree Cure Hub?

All you have to do is create your free account at healthtree.org, complete your profile and find treatment options (including clinical trials) that meet your specific needs.

Remember that the only way to advance is to investigate as much as possible. This is the reason why enrolling into clinical trials is our best shot to find a cure.

The author Eduardo Franco

about the author
Eduardo Franco

Eduardo Franco is an International Medical Graduate who Joined HealthTree in 2020 as part of The Patient Experience team. He reads the patient’s medical records and compares them with the information reported by patients on Healthtree so we can have the most exact information on our platform. He is a martial arts practitioner, drummer and avid reader.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube